HSK 3486

Drug Profile

HSK 3486

Alternative Names: HSK-3486

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Sichuan Haisco Pharmaceutical
  • Class General anaesthetics
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anaesthesia

Most Recent Events

  • 19 Nov 2016 Sichuan Haisco Pharmaceutical plans a phase I trial in Healthy volunteers in Australia (ACTRN12616001620415)
  • 07 Apr 2014 Phase-I clinical trials in Anaesthesia (in volunteers) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top